GlassScriptPhysician profile
Jamie M Schneider
NPI 1245791847
$3,263.68
in general payments reported to CMS, 2019-2025
35 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $983 · 2022: $913 · 2023: $880 · 2024: $367 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,318 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,317.82 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $715.77 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $531.84 | 2021-2025 | |
| Glaxosmithkline, LLC. | $275.37 | 2021-2025 | Trelegy Ellipta |
| Novo Nordisk INC | $218.50 | 2021-2023 | Ozempic, Rybelsus |
| Lilly USA, LLC | $164.68 | 2021-2023 | Mounjaro |
| Amarin Pharma, INC. | $138.59 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.82 | 2021-2025 | Xifaxan |
| Sumitomo Pharma America, INC. | $93.71 | 2023-2024 | Gemtesa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $87.80 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $74.72 | 2021-2023 | Spravato |
| Novartis Pharmaceuticals Corporation | $70.21 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.89 | 2021-2023 | |
| Currax Pharmaceuticals LLC | $62.04 | 2022-2023 | Nexletol |
| Axsome Therapeutics, INC. | $59.88 | 2023 | Sunosi |
| Exact Sciences Corporation | $51.59 | 2023 | Cologuard Collection Kit |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $50.90 | 2021-2025 | Repatha, Otezla |
| Nestle Healthcare Nutrition INC. | $50.11 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $46.05 | 2022-2023 | Livalo, Seglentis |
| Optinose US, INC. | $43.35 | 2022 | |
| Merck Sharp & Dohme LLC | $38.45 | 2022 | |
| Pfizer INC. | $36.95 | 2023-2024 | |
| Sunovion Pharmaceuticals INC. | $32.78 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.93 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $28.94 | 2021 | |
| Astellas Pharma US INC | $28.77 | 2021-2023 | Veozah |
| Tris Pharma INC | $24.13 | 2024 | Dyanavel Xr |
| Jazz Pharmaceuticals INC. | $20.38 | 2021 | |
| Eisai INC. | $16.95 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $16.54 | 2023 | Nuedexta |
| Abbott Laboratories | $16.14 | 2024 | Proclaim |
| Sanofi-Aventis U.S. LLC | $14.76 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $14.74 | 2021 | |
| Apria Healthcare LLC | $13.95 | 2021 | |
| Esperion Therapeutics, INC. | $13.64 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Schneider listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.